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In two previous articles in this issue of SAMJ, the legal regulation of 
human faecal microbial transplantation (FMT) has been addressed. [1,2] 
In those articles, the important role of FMT as an effective treatment 
for recurrent Clostridioides difficile infection (CDI), which is a major 
cause of morbidity and mortality, was discussed. The articles also 
emphasised the uncertainty regarding the ethicolegal regulation of 
microbiome-based therapy and research in a legal context in South 
African (SA) law. The second article in the series addressed the 
issue of the categorisation of human stool as human tissue in terms 
of the National Health Act 61 of 2003 (NHA), as well as the legal 
requirements for a stool bank. In this article, the focus will turn to 
processed human stool as medicine or medical treatment.
The nature of FMT is unique and different from conventional 
medicines or therapies. It may include characteristics and components 
of a ‘health service’ in terms of the NHA, which includes medical 
treatment, or a ‘medicine’ as described in the Medicines and Related 
Substances Act 101 of 1965 (MRSA). Each of these has different legal 
and ethical considerations, depending on the nature of the procedure.
If administered orally by way of swallowing capsules containing 
processed faecal microbial material, this type of microbial treatment 
arguably enters the realm of the registration of medicines. The 
administration of minimally processed microbial matter via 
nasoduodenal tube or colonoscopy would arguably resemble medical 
treatment. The confusion regarding the exact nature of an FMT 
also appears from the US Food and Drug Administration (FDA)’s 
position on the issue, which has shifted a few times in recent 
years.[3] The FDA currently classifies FMTs as a drug (e.g. a live 
biotherapeutic product), a position it took since May 2013, subject to 
enforcement discretion of not requiring an Investigational New Drug 
(IND) application for doctors performing the procedure and stool 
banks providing faecal matter for patients with CDI unresponsive to 
standard therapies.[3,4]
In March 2016, however, the FDA published a draft guidance 
document that requires stool banks to submit an IND application 
to obtain and distribute stool to doctors. However, the IND would 
not be applied in the case of doctors collecting and screening donor 
stool and performing the procedure, or for entities such as hospital 
laboratories that collect and prepare FMT products ‘solely under the 
direction of licensed health care providers’ for use by the patients 
of the provider.[5] This draft guidance was never implemented and 
therefore never superseded the 2013 guidance, owing to significant 
objection from clinicians and patient advocates. More recently in June 
2019, the FDA issued a safety alert on the risk of serious infections 
caused by multidrug-resistant organisms related to the investigational 
use of faecal microbiota for transplantation, following the death of an 
immunocompromised patient who received an investigational FMT.
Different regulatory systems may regulate FMT as both a product 
and a procedure that combines different approaches for the treatment 
of drugs, blood and human tissue for transplantation, or view it 
as part of the practice of medicine (e.g. clinical treatment).[3] The 
regulatory pathway would depend on the exact composition of the 
FMT and the relevant formulations or levels of manipulation of the 
stool, which may range from basic frozen stool to capsules containing 
frozen stool, or lyophilised powder or defined microbial consortia.[5] 
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The purpose of this article, the last in a series of three exploring the legal framework for the regulation of faecal microbiota transplantation 
(FMT) in South Africa (SA), is to determine the regulatory framework that applies to microbial-based treatments involving a level of 
manipulation that exceeds that of basic stool transplantation, e.g. processed FMT-derived products in capsule form. The article highlights 
the legal requirements for the registration of these products as biological medicines in SA law. Although human stool banks are not regulated 
in terms of the National Health Act 61 of 2003 (NHA) and regulations, the earlier articles point out that human stool fits the definition of 
human tissue and human biological material as defined by the NHA. For this reason, stool banks should be considered tissue banks in terms 
of the NHA and regulations. Healthcare practitioners and researchers involved in FMT banking and transplantation should strive to comply 
with these regulations in the absence of clear legal direction at present.
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Stool-based products containing specific bacterial strains aimed at 
treating specific diseases involve a higher level of manipulation and a 
more target-specific approach. The level of manipulation of the stool 
is critical in the determination of the relevant regulatory pathway, as 
FMTs involving material that is ‘more than minimally manipulated’ 
may require registration as a medicine (e.g. a biological), as is the 
case in the USA. Human cells, tissue, and cellular and tissue-based 
products not meeting these criteria, however, are also subject to the 
good tissue practice requirements and will in addition be regulated 
as drugs, biologicals or devices under section 351 of the Public 
Health Services Act and Title 21 of the Code of Federal Regulations 
(1271.20).[6]
In the most elementary FMT procedure, faeces are homogenised 
in a liquid buffer such as saline or glycerol – this indicates minimal 
manipulation. The FDA’s definition of ‘minimal manipulation’ refers 
to ‘processing that does not alter the relevant biologic characteristics 
of cells or tissue’.[6] According to Hoffmann et al.,[3] the degree of 
manipulation of stool may vary as follows from the least to the 
most manipulated: (i) fresh stool transferred from an individual 
donor; (ii) frozen filtered stool from a stool bank; (iii) concentrated 
stool microbiota in capsule form; (iv) biologically sourced, purified 
microbial groups of specific bacterial strains; and (v) cultured 
bacterial mixture delivered in oral pill form.
The first two, (i) and (ii), will be applicable if human stool is treated 
as tissue, as discussed in our first article in the series of three. The last 
two, (iv) and (v), will be regarded as highly manipulated stool-derived 
products, and a different regulatory framework will therefore apply 
to these products compared with that if basic stool was classified 
as tissue. The classification of (iii) is less clear. FMT capsules may 
contain the same faecal slurry as is administered via colonoscopy or 
nasogastric tube, pointing to material that is minimally manipulated, 
as there is no additional processing of the material, except aliquoting 
the material into the capsules. This position is very different from 
capsular administration, generally considered a form of upper 
gastrointestinal tract administration. Even if the faecal donation is 
not manipulated, the faecal material still requires careful testing and 
preparation. In view of this dilemma, we argue that a South African 
Health Products Regulatory Authority (SAHPRA) determination is 
urgently needed in order to extend oversight over this area, requiring, 
for example, registration of the person or entity preparing FMT 
products and stipulating standards for testing.
Oral administration of faecal 
microbiota
Trial sites in the USA and Canada are currently enrolling patients for 
clinical trials involving freeze-dried oral FMT capsules that contain 
healthy gut bacteria.[7] The THRIVE study, a first global study of FMT 
in paediatric malnutrition as a small phase I study that will investigate 
whether faecal transplantation may assist severely malnourished 
children who fail to develop even after their nutritional needs are 
met, is worth mentioning.[8] Any medicine containing processed 
faecal matter that will be distributed and sold in SA should comply 
with the requirements for the registration of medicines in terms of 
the MRSA. Since the FDA considers FMT to be a biological medicine, 
it is necessary to consider the requirements regarding biological 
medicines in SA.
The SAHPRA, which has been established to replace the Medicines 
Control Council, oversees the regulation of health products, which 
include medicines, medical devices, in vitro diagnostic tests and 
devices, radiation-emitting products, and devices used in healthcare 
and industry.
SAPHRA’s General Information Guideline of May 2019, titled 
‘Guidance for the Submission of the South African CTD/eCTD – 
General & Module 1’,[9] provides recommendations for applicants 
preparing a common technical document for the registration of 
medicines for submission to SAHPRA. Legislation requires that 
every medicine is registered with SAHPRA before it may be sold 
or marketed[10] (also see the National Department of Health’s 2006 
Guidelines for Good Practice in the Conduct of Clinical Trials[11]). 
An application for the registration of a medicine should therefore be 
submitted for evaluation and approval.
The sale of medicine that is subject to registration but not 
registered is prohibited in terms of section 14(1) of the MRSA. 
Section 14(4) of the MRSA provides an exception where such 
medicine is compounded in the course of the carrying on of his or 
her profession by inter alia a medical practitioner for a particular 
patient, in a quantity not greater than that required for treatment 
as determined by such medical practitioner. A particular substance 
must be used relatively widely for therapeutic purposes and not 
only on a ‘single occasion’ in order for the substance to qualify as a 
‘medicine’ in terms of the MRSA.[12]
The MRSA defines a medicine in section 1 as: 
 ‘any substance or mixture of substances used or purporting to be 
suitable for use or manufactured or sold for use in -
 (a) the diagnosis, treatment, mitigation, modification or prevention 
of disease, abnormal physical or mental state or the symptoms 
thereof in man; or
 (b) restoring, correcting or modifying any somatic or psychic or 
organic function in man, and includes any veterinary medicine.’
Biological medicines, a highly specialised class or type of medicine, 
produced using living organisms, are complex protein structures 
typically much larger than traditional chemical medicines, and are 
mostly administered by injection. Biological medicines are more 
advanced than conventional therapies and provide prescribers with 
enhanced tools for treating patients.[13] The MRSA does not define 
a biological medicine, but SAHPRA’s website describes biological 
medicines as products ‘produced from living organisms or contain 
components of living organisms’.[14] Biological medicines include ‘a 
variety of products derived from human, animal or microorganisms 
by using biotechnology’. Types of biological medicines include 
vaccines, blood, blood components, biotherapeutics, biosimilar and 
recombinant proteins. Biological products may contain proteins that 
control the action of other proteins and cellular processes, genes that 
control production of vital proteins, modified human hormones, or 
cells that produce substances that suppress or activate components of 
the immune system.[14]
The above understanding of biological medicines would arguably 
include faecal material that is manipulated for oral administration via 
capsule and other routes of administration (such as an enema FMT-
derived product). Since the MRSA requires that SAHPRA shall register 
every medicine before it may be sold and marketed, an application for 
the registration of a medicine should be submitted for evaluation 
and approval in accordance with SAHPRA’s General Information 
Guideline,[9] as well as the Clinical Guideline.[15] Applications for 
registration of a medicine for use in humans are divided into different 
types for the determination of fees and allocation to reviewers for 
evaluation. As such, a biological medicine is one of the types of 
medicines applicable. It is a legal requirement that data submitted 
for evaluation, by the applicant, should substantiate all clinical claims 
and should meet the technical requirements of quality, safety and 
efficacy. SAHPRA refers to international guidelines to be read in 
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conjunction with the SA guidelines. In particular, reference is made 
to the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 
(ICH),[16] the mission of which is to achieve greater harmonisation to 
ensure that safe, effective and high-quality medicines are developed 
and registered in the most resource-efficient manner, as well as to the 
European Medicines Agency.[17]
The ICH promotes public health, prevents unnecessary duplication 
of clinical trials in humans, and minimises the use of animal testing 
without compromising safety and effectiveness.[16] Therefore, any 
applicant for the registration of a medicine must ensure that the 
technical requirements of quality, safety and efficacy of the product 
for the purposes for which it is intended have been met. After 
submission of the relevant administrative steps for the registration 
of a medicine (which includes biological medicine), these biological 
medicines (containing or derived from living materials) require 
primary evaluation by the Biological Medicines Committee, in 
addition to other committees of SAHPRA. The Biological Medicines 
Evaluation and Research Unit (BMERU), a sub-unit of medicines 
evaluation within SAHPRA, is tasked with the evaluation of 
applications for registration of biological medicines.
SAHPRA may choose to accept, defer or reject the application. 
Should the application be deferred, the applicant will be required to 
produce additional information and re-submit the application for 
approval. Once the application is accepted, the biological medicine is 
registered with SAHPRA and may be sold and marketed.
Failure to register an FMT in the prescribed manner, accepting that 
it falls within the scope of a biological medicine, would constitute a 
contravention of section 14(1) of the MRSA and hence an offence in 
terms of section 29, punishable by virtue of section 30 by a fine or 
imprisonment for a period not exceeding 10 years.
Microbiota-based products as 
probiotics?
For the purpose of this article, it is necessary to consider whether 
FMT is more aligned with probiotics than a biological medicine. One 
major difference between FMT and probiotics is that the former graft 
in a patient’s gut after administration, whereas the latter usually do 
not. Probiotics are not licensed to treat specific disease indications, 
and have not undergone phase I, II and III efficacy trials. In the USA, 
FMT-derived products are currently undergoing these efficacy trials. 
Probiotics in SA are regulated by SAPHRA in terms of the January 
2020 Complementary Medicines – Discipline-Specific Safety and 
Efficacy guideline,[18] the aim of which is to provide clear guidance 
with regard to the safety and efficacy requirements for registration of 
discipline-specific complementary medicines in SA in the common 
technical document format, in order to ensure that the levels of 
evidence for safety and efficacy are rigorous enough to protect public 
health and maintain consumer confidence.[18] Not only are there 
clearly very few commonalities between FMT-derived products and 
probiotics, but their regulatory frameworks are also different.[19]
Conclusions
The purpose of this article was to explore the regulatory framework 
that applies to microbial-based treatments involving a level of 
manipulation that exceeds that of basic stool transplants, for example 
concentrated stool microbiota in capsule form. The article highlights 
the legal requirements for registration of these products as biological 
medicines in SA law. The article also concludes that FMT-derived 
products have few similarities to probiotics. This discussion is an 
addition to the previous article, which analyses the legal requirements 
relating to the use and transplantation of stool as part of human tissue 
regulation under the scope of chapter 8 of the NHA and regulations. 
Although human stool banks are not regulated in terms of the NHA 
and regulations, the previous article points out that human stool 
fits the definition of human tissue and human biological material as 
defined by the NHA. For this reason, stool banks could be considered 
as tissue banks in terms of the NHA and regulations and should 
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